Publication date: Jul 13, 2024
To evaluate the impact of the pandemic on the consumption of antidepressive agents in Central Portugal. To estimate the causal effect of the pandemic an interrupted time series analysis was conducted. Data of antidepressant drugs monthly dispensed in community pharmacies between Jan-2010 and Dec-2021 were provided by the regional Health Administration. Anti-Parkinson dopaminergic agents and statins, theoretically not influenced by COVID-19 pandemics, were used as comparator series. The number of packages was converted into defined daily doses and presented as defined daily doses/1000 inhabitants/day. A Bayesian structural time-series model with CausalImpact on R/RStudio was used to predict the counterfactual. Analyses with different geographical granularity (9 sub-regions and 78 municipalities) were performed. When compared to counterfactual, regional consumption non-significantly increased after the pandemic declaration, with a relative effect of + 1. 30% [95%CI -1. 6%:4. 2%]. When increasing the granularity, differences appeared between sub-region with significant increases in Baixo Mondego + 6. 5% [1. 4%:11. 0%], Guarda + 4. 4% [1. 1%:7. 7%] or Cova da Beira + 4. 1% [0. 17%:8. 3%], but non-significant variation in the remaining 6 sub-regions. Differences are more obvious at municipality level, ranging from increases of + 37. 00% [32. 00%:42. 00%] to decreases of -11. 00% [-17. 00%:-4. 20%]. Relative impact positively correlated with percentage of elderly in the municipality (r = 0. 301; p = 0. 007), and negatively with population density (r=-0. 243; p = 0. 032). No other predicting variables were found. Antidepressant consumption suffered very slight variations at regional level after the COVID-19 pandemic declaration. Analysis with higher granularity allowed identifying municipalities with higher impact (increase or decrease). The absence of clear association patterns suggests other causal hypotheses of the differences.
Open Access PDF
Concepts | Keywords |
---|---|
Antidepressive | Antidepressive agents |
Bayesian | COVID-19 |
Monthly | Drug utilization |
Parkinson | Pharmacoepidemiology |
Pharmacies |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | COVID-19 pandemic |
disease | VO | time |
disease | VO | monthly |
disease | VO | population |
drug | DRUGBANK | Indoleacetic acid |
disease | MESH | unemployment |
drug | DRUGBANK | Ethanol |
disease | VO | vaccination |
disease | MESH | infectious diseases |
drug | DRUGBANK | Serine |
disease | MESH | suicidal ideation |
disease | MESH | psychological distress |
disease | MESH | anxiety disorder |
disease | MESH | dementia |
disease | MESH | psychiatric disorders |
disease | VO | organization |
drug | DRUGBANK | Timonacic |
drug | DRUGBANK | Coenzyme M |
disease | IDO | intervention |
drug | DRUGBANK | Tretamine |
disease | IDO | country |
disease | IDO | process |
drug | DRUGBANK | Pirlindole |
disease | VO | dose |
drug | DRUGBANK | Esomeprazole |
drug | DRUGBANK | Hexocyclium |
drug | DRUGBANK | Serotonin |
drug | DRUGBANK | Pirenzepine |
disease | VO | Equity |
disease | MESH | loneliness |
disease | VO | Canada |
disease | MESH | post traumatic stress disorders |
drug | DRUGBANK | Trestolone |
disease | MESH | suicide |
disease | MESH | Retirement |
drug | DRUGBANK | Buprenorphine |
drug | DRUGBANK | Benzodiazepine |